Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Zhenggang Ren(Ministry of Education of the People's Republic of China), Jianming Xu(Chinese PLA General Hospital), Yuxian Bai(Harbin Medical University), Aibing Xu(Nantong Tumor Hospital), Shundong Cang(Henan Provincial People's Hospital), Chengyou Du(The Affiliated Yongchuan Hospital of Chongqing Medical University), Qiu Li(Sichuan University), Yinying Lu(Chinese PLA General Hospital), Yajin Chen(Sun Yat-sen University), Yabing Guo(Nanfang Hospital), Zhendong Chen(Anhui Medical University), Baorui Liu(Nanjing Drum Tower Hospital), Weidong Jia(Anhui Provincial Hospital), Jian Wu(Nanchang University), Junye Wang(Second Affiliated Hospital of Xi'an Jiaotong University), Guoliang Shao(Zhejiang Cancer Hospital), Bixiang Zhang(Huazhong University of Science and Technology), Yunfeng Shan(Wenzhou Medical University), Zhiqiang Meng(Fudan University Shanghai Cancer Center), Jianbing Wu(Nanchang University), Shanzhi Gu(Hunan Cancer Hospital), Wei Yang(First Affiliated Hospital of Xi'an Jiaotong University), Chao Liu(Sun Yat-sen University), Xuetao Shi(Shandong Tumor Hospital), Zhenyuan Gao(First Affiliated Hospital of Bengbu Medical College), Tao Yin(Hubei Cancer Hospital), Jiuwei Cui(Jilin University), Ming Huang, Bao-Cai Xing(Peking University), Yilei Mao(Chinese Academy of Medical Sciences & Peking Union Medical College), Gao‐Jun Teng(Zhongda Hospital Southeast University), Yanru Qin(First Affiliated Hospital of Zhengzhou University), Jinhai Wang(Second Affiliated Hospital of Xi'an Jiaotong University), Feng Xia(Southwest Hospital), Guowen Yin(Jiangsu Cancer Hospital), Yong Yang, Mingxia Chen, Yan Wang, Hui Zhou, Jia Fan(Ministry of Education of the People's Republic of China)
Cited by 1,093
Abstract
Related Papers
No related papers found
Powered by citation graph analysis